Valiant Organics Q1 FY25 earnings call: Revenue & Margins
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹168Cr
- −5.1% QoQ
- Net profit
- −₹1Cr
- Margin
- 9%
- +10.2 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Valiant Organics Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1-FY25 Revenue from Operations: INR 1,679 Mn - Year-on-Year Revenue Change: - Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13) - Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12) - Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24): - Chlorination: 660 MT vs 697 MT - Hydrogenation: 543 MT vs 475 MT - Ammonolysis: 118 MT vs 127 MT - Others: 333 MT vs 271 MT (Page 11) - Explicit Outlook: - Demand in dyes and pigments industry has improved with optimism for agrochemicals and pharmaceuticals sectors to increase demand soon. Q1-FY25 Consolidated EBITDA: INR 157 Mn, down 34.3% YoY (from INR 239 Mn in Q1-FY24) - Q1-FY25 Consolidated EBITDA Margin: 9.35%, down 249 bps YoY (from 11.84% in Q1-FY24) - Q1-FY25 Consolidated P
From Valiant Organics Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1-FY25 Revenue from Operations: INR 1,679 Mn
- Year-on-Year Revenue Change:
- Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13)
- Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12)
- Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24):
- Chlorination: 660 MT vs 697 MT
- Hydrogenation: 543 MT vs 475 MT
- Ammonolysis: 118 MT vs 127 MT
- Others: 333 MT vs 271 MT (Page 11)
- Explicit Outlook:
2 more points from Valiant Organics Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Valiant Organics Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Valiant Organics Ltd said on order book & pipeline — free account, 30 seconds.
Valiant Organics Ltd — Quarterly revenue & net profit
Valiant Organics Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q4 FY24 | QoQ |
|---|---|---|---|
| Revenue | 168 | 177 | -5.1% |
| Operating profit (EBITDA) | 16 | -2 | — |
| Operating margin | 9% | -1.2% | +10.2 pp |
| Profit before tax | 2 | -25 | — |
| Net profit (PAT) | -1 | -20 | — |
| EPS (₹) | -0.22 | -7.32 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹304 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Himadri Special (Q1 FY25)
1,199.77 Cr, up 26.17% YoY (vs Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- Balaji Amines (Q1 FY25)
Q1FY25 consolidated revenue from operations: ₹393 crore, down 16% YoY from ₹469 crore in Q1FY24 (Page 5 & 6). Key concall takeaways from Balaji Amines Ltd's Q1…
- Linde India (Q1 FY25)
Revenue for year ended Mar 2024: ₹27,687 million, down 12% vs. Key concall takeaways from Linde India Ltd's Q1 FY25 earnings call — and how it ranks against…
- Vidhi Specialty (Q1 FY25)
83.0 Crs, up 4.1% year-on-year from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY25 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Valiant Organics Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Valiant Organics Ltd Q1 FY25 results?
Q1-FY25 Revenue from Operations: INR 1,679 Mn - Year-on-Year Revenue Change: - Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13) - Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12) - Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24): - Chlorination: 660 MT vs 697 MT - Hydrogenation: 543 MT vs 475 MT - Ammonolysis: 118 MT vs 127 MT - Others: 333 MT vs 271 MT (Page 11) - Explicit Outlook: - Demand in dyes and pigments industry has improved with optimism for agrochemicals and pharmaceuticals sectors to increase demand soon. Q1-FY25 Consolidated EBITDA: INR 157 Mn, down 34.3% YoY (from INR 239 Mn in Q1-FY24) - Q1-FY25 Consolidated EBITDA Margin: 9.35%, down 249 bps YoY (from 11.84% in Q1-FY24) - Q1-FY25 Consolidated P
What is Valiant Organics Ltd share price analysis?
Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
